Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2021; 9(36): 11173-11182
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11173
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11173
Analysis of the incidence and influencing factors of hyponatremia before 131I treatment of differentiated thyroid carcinoma
Jing-Jia Cao, Can-Hua Yun, Juan Xiao, Yong Liu, Wei Wei, Wei Zhang, Department of Nuclear Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong Province, China
Author contributions: Cao JJ, Yun CH, Xiao J, Liu Y and Wei W contributed acquisition of data; Cao JJ, Yun CH and Xiao J contributed analysis of data, drafting the article; Zhang W conceived and designed the study; all authors have read and approved the final manuscript.
Institutional review board statement: The study was approved by the Institutional Review Board of the Second Hospital, Cheeloo College of Medicine, Shandong University (KYLL-2018[LW]013). All procedures complied with the Declaration of Helsinki for research involving human subjects.
Informed consent statement: Written informed consent was obtained from each patient.
Conflict-of-interest statement: All authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Zhang, MD, Professor, Department of Nuclear Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, No. 247 Road, Tianqiao District, Jinan 250033, Shandong Province, China. sdeyzhangwei@126.com
Received: May 11, 2021
Peer-review started: May 11, 2021
First decision: July 8, 2021
Revised: August 3, 2021
Accepted: November 15, 2021
Article in press: November 15, 2021
Published online: December 26, 2021
Processing time: 226 Days and 11 Hours
Peer-review started: May 11, 2021
First decision: July 8, 2021
Revised: August 3, 2021
Accepted: November 15, 2021
Article in press: November 15, 2021
Published online: December 26, 2021
Processing time: 226 Days and 11 Hours
Core Tip
Core Tip: We analyzed the incidence and influencing factors of hyponatremia in patients with differentiated thyroid cancer (DTC) before 131I treatment. We evaluated 903 postoperative DTC patients who received 131I treatment. The results suggest that the incidence of hyponatremia induced by 131I treatment preparation was not high. The identified influencing factors of hyponatremia included history of diuretic use, distant metastases, preoperative sodium and blood urea nitrogen. Our findings may help to improve patient management during the preparation period for 131I treatment.